PubMed · 2006 · 25 citations · 0 references
PharmacyHematologyPharmacotherapyAutoimmunityClinical ImmunologyImmunopathologyAnemiaAntiviral TherapyAutoimmune DiseasesInterferon-based TherapyViral HepatitisViral Hepatitis TreatmentAutoimmune Hepatitis TreatmentChronic Viral HepatitisCombination TherapyHematological AnalysisInterferon Alfa TherapyPegylated Interferon AlfaRibavirin TherapySevere Anemia
Peginterferon (Peg-IFN) alfa in combination with ribavirin represents the gold standard treatment for chronic hepatitis C, but is associated with various side effects, especially hematological abnormalities. We report here a case of severe autoimmune hemolytic anemia (AIHA) complicated by symptomatic myocardial ischemia in a patient with chronic hepatitis C during combination therapy. The worsening hemolysis after ribavirin withdrawal and exclusion of other causes implicated Peg-IFN alfa as the cause of AIHA. Our study demonstrates that in patients without preexisting immunological abnormalities Peg-IFN can de novo induce autoimmune complications that, albeit rarely, may be life-threatening.